STOCK TITAN

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Applied DNA Sciences, Inc. (NASDAQ:APDN) has been awarded a contract by HDT Bio for rapid vaccine development, aiming to manufacture mRNA vaccines within 7 days. The project focuses on decentralized vaccine manufacturing to combat infectious diseases.
Applied DNA Sciences, Inc. (NASDAQ:APDN) ha ricevuto un contratto da HDT Bio per lo sviluppo rapido di vaccini, con l'obiettivo di produrre vaccini a mRNA entro 7 giorni. Il progetto si concentra sulla produzione decentralizzata di vaccini per combattere le malattie infettive.
Applied DNA Sciences, Inc. (NASDAQ:APDN) ha sido premiada con un contrato por parte de HDT Bio para el desarrollo rápido de vacunas, con el objetivo de fabricar vacunas de ARNm en un plazo de 7 días. El proyecto se enfoca en la fabricación descentralizada de vacunas para luchar contra enfermedades infecciosas.
Applied DNA Sciences, Inc. (NASDAQ:APDN)는 HDT Bio로부터 빠른 백신 개발을 위한 계약을 수상했으며, 7일 내에 mRNA 백신을 제조하는 것을 목표로 합니다. 이 프로젝트는 감염병을 퇴치하기 위한 분산 백신 제조에 중점을 둡니다.
Applied DNA Sciences, Inc. (NASDAQ:APDN) a reçu un contrat de HDT Bio pour le développement rapide de vaccins, dans le but de fabriquer des vaccins à ARNm dans les 7 jours. Le projet se concentre sur la fabrication décentralisée de vaccins pour lutter contre les maladies infectieuses.
Applied DNA Sciences, Inc. (NASDAQ:APDN) hat von HDT Bio einen Vertrag für die schnelle Entwicklung von Impfstoffen erhalten, mit dem Ziel, mRNA-Impfstoffe innerhalb von 7 Tagen herzustellen. Das Projekt konzentriert sich auf die dezentralisierte Herstellung von Impfstoffen zur Bekämpfung von Infektionskrankheiten.
Positive
  • None.
Negative
  • None.

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days

STONY BROOK, NY / ACCESSWIRE / April 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler' award to HDT Bio (the "Project"). The Project seeks to facilitate the rapid production of vaccines during outbreaks/pandemics, focusing on decentralized vaccine manufacturing, with vaccines deemed critical medical countermeasures to infectious disease threats.

Under the terms of the contract, Applied DNA will supply Linea™ DNA IVT templates to HDT Bio for use in conjunction with its LION™ formulated repRNA (self-replicating RNA) vaccination platform. The goal of the contract is to demonstrate the feasibility of manufacturing 1,000 doses of a functional vaccine within seven days.

About the Linea DNA and Linea™ IVT Platforms

The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.

The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.

About HDT Bio

HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio's work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company's vaccine platforms combine formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses. HDT Bio's repRNA/LION™ is the first self-amplifying RNA vaccine platform to ever receive a regulatory authorization.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the inherent risk and unknown outcome of research and development projects, the unknown amount of revenues and profits that will result from the Linea DNA™ and/or Linea™ IVT platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for human therapeutic use and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 7, 2023, as amended, its Form 10-Q filed on February 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts:

Applied DNA Sciences

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com

Web: www.adnas.com

Twitter: @APDN

SOURCE: Applied DNA Sciences, Inc.



View the original press release on accesswire.com

FAQ

What contract has Applied DNA Sciences, Inc. (APDN) been awarded?

Applied DNA Sciences, Inc. (NASDAQ:APDN) has been awarded a contract by HDT Bio for rapid vaccine development.

What is the goal of the contract between Applied DNA Sciences, Inc. (APDN) and HDT Bio?

The goal of the contract is to demonstrate the feasibility of manufacturing 1,000 doses of a functional vaccine within seven days.

What technology will Applied DNA supply to HDT Bio for the contract?

Applied DNA will supply Linea DNA IVT templates to HDT Bio for use in conjunction with its LION formulated repRNA vaccination platform.

What is the focus of the project awarded to Applied DNA Sciences, Inc. (APDN) by HDT Bio?

The project focuses on decentralized vaccine manufacturing to combat infectious diseases.

Applied DNA Sciences, Inc.

NASDAQ:APDN

APDN Rankings

APDN Latest News

APDN Stock Data

9.37M
41.55M
0.62%
0.5%
0.94%
Diagnostics & Research
Services-testing Laboratories
Link
United States of America
STONY BROOK